Epitalon peptide (Epithalon; AEDG, Ala-Glu-Asp-Gly) can be dissolved for laboratory purposes, although peer-reviewed scientific literature does not specify a single universal solvent for reconstitution, storage temperature, shelf-life after reconstitution, or the permissible number of freeze-thaw cycles. These conditions should therefore be based on stability data validated for the specific product, rather than on general assumptions regarding peptide handling. [1–3]
Searches concerning topics such as Epithalon 10 mg reconstitution, bacteriostatic water, storage in the refrigerator, or „how long does Epitalon remain stable after reconstitution” often lead to very precise instructions originating from commercial sources. Scientific literature, however, is significantly less unambiguous. Published Epitalon studies describe how researchers prepared experimental solutions for specific cell culture studies, but these methods were developed for those particular experiments and typically did not include formal stability studies determining how long an unopened lyophilised vial or reconstituted research preparation retains its chemical identity, purity, potency, sterility, or biological activity.
This distinction is important. Solubility is not the same as stability, and stability is not the same as sterility. A peptide can dissolve completely while at the same time undergoing chemical degradation. A solution containing a chemically unchanged peptide can become microbiologically contaminated. Conversely, a product can remain sterile yet lose its activity due to degradation or aggregation.
What does Epitalon reconstitution mean?
Reconstitution of Epitalon means adding an appropriate, validated solvent to the dry or lyophilised Epitalon preparation in order to obtain a solution of a specific concentration for a particular laboratory procedure. Reconstitution alone does not confirm stability, sterility, bioavailability or suitability for human use.
The term reconstitution is of the greatest importance when the material is supplied as a dry powder or freeze-dried preparation.
Lyophilisation consists of removing water from a frozen formulation under controlled conditions. In pharmaceutical product development, its aim is often to improve the storage properties of substances that may be less stable in an aqueous solution. However, the mere appearance of the lyophilised powder does not prove that a specific peptide remains stable for a given period of time.
Published Epitalon research confirms that the peptide can be prepared in aqueous laboratory solutions.
A 2025 study on human retinal pigment epithelial cells reported that the Epitalon supplied to the researchers was dissolved in water to prepare a concentrated stock solution, which was then diluted in culture medium to concentrations of 20, 40 and 60 ng/mL. [2]
In another 2025 study on telomeres in human cells, an Epitalon stock solution was prepared using bacteriostatic water, and then significantly lower experimental concentrations were added to breast cancer cell cultures, fibroblasts, and epithelial cells. [3]
These examples show that Epitalon was dissolved in more than one type of aqueous laboratory medium.
However, they do not establish a single standardised method of reconstitution for all Epitalon materials.
Differences regarding peptide salt form, purity, residual moisture, excipients, packaging system, analytical specification, type of experiment and sterility requirements can affect the appropriate preparation method.
Why does bacteriostatic water appear in searches regarding Epitalon?
Bacteriostatic water appears in searches relating to Epitalon partly because one of the more recent in vitro studies used it to prepare an experimental Epitalon stock solution, and also because it is a recognised sterile pharmaceutical diluent containing a preservative. However, its use in a single laboratory study does not mean that it is a universal or preferred medium for the reconstitution of Epitalon. [3]
The most direct link between Epitalon and bacteriostatic water comes from a 2025 publication by Al-Dulaimi and colleagues in Biogerontology.
In this in vitro experiment on human cells, researchers reported that they prepared an Epitalon stock solution using bacteriostatic water prior to exposing the cultured cells to experimental concentrations. [3]
This method concerned that specific experiment.
In another 2025 study, Epitalon, ordinary laboratory water was used to prepare the stock solution for ARPE-19 retinal pigment epithelial cells. [2]
Therefore, the reviewed literature on Epitalon itself shows that bacteriostatic water is not the only solvent used experimentally.
From a pharmaceutical perspective, Bacteriostatic Water for Injection is a recognised sterile diluent containing a bacteriostatic agent. FDA documentation describes the USP product as sterile water containing 0.9% of benzyl alcohol.
However, this information should not be turned into a recommendation regarding Epitalon.
The appropriate diluent for each validated pharmaceutical or laboratory formulation depends on the specific product specifications. General FDA guidelines on lyophilised products also emphasise that the reconstitution medium and the validated stability of the reconstituted preparation are product-specific matters.
Therefore, the most precise scientific conclusion is:
Bacteriostatic water was used in at least one Epitalon cell culture study, but published evidence does not indicate that it is a universally required solvent for Epitalon.
How to Interpret a 10 mg Epithalon Vial in Laboratory Work?
An Epithalon 10 mg vial denotes the nominal total peptide mass of 10 milligrams in a given container. It does not specify the final concentration, solvent volume, purity, salt form, stability, sterility, or the number of potential experimental applications. All these parameters should be determined by the product specification and the study design.
The designation 10 mg describes mass, not concentration.
Concentration can only be determined once the amount of material is related to a specific volume of solution. The choice of this volume is part of the experimental design and cannot be deduced solely from the size of the flask.
This distinction is of particular importance because significantly different final concentrations of Epitalon were used in various published studies.
In a 2025 retinal cell study, ARPE-19 cells were exposed to 20, 40 or 60 ng/mL. [2]
In the 2025 telomere study, breast cancer cells were exposed to 0.1, 0.2, 0.5, or 1.0 μg/mL, while normal fibroblasts and mammary epithelial cells were exposed to 1.0 μg/mL. [3]
These are experimental concentrations in cell culture, not instructions for using the 10 mg vial.
The vial label also does not need to explain whether the given mass refers solely to the free peptide or also includes the salt, counterion, water, excipients, or other formulation ingredients.
For this reason, documentation confirming the identity and content marked by the analytical method is of significant importance.
A comprehensive 2025 review of Epitalon indicates that Epitalon occurs in various chemical contexts, including as a salt, and draws attention to the relatively limited physicochemical characterisation of the peptide compared to the extensive biological literature. [1]
In laboratory work, the vial specification should therefore clearly state what the declared 10 mg actually means.
What factors affect the stability of peptides?
Peptide stability can be affected by sequence, pH, solvent composition, temperature, light, contact with oxygen, concentration, salt form, residual moisture, impurities, interactions with packaging material, freeze-thaw stress, and microbial contamination. However, the degradation rate of Epitalon depending on these factors has not been adequately determined in published stability studies.
It is crucial to distinguish general peptide chemistry from Epitalon-specific evidence.
Epitalon is a very short tetrapeptide, but its small size does not mean that its stability can be reliably predicted solely on that basis.
A 2025 review of Epitalon indicates that short peptides, such as Epitalon, typically undergo rapid degradation in vivo, while also noting that strategies commonly used to increase peptide stability, such as chemical modifications of the molecule's termini, have not been adequately studied in the case of Epitalon. [1]
However, in vivo metabolic stability is something different from stability in a vial.
A peptide may undergo rapid degradation by biological enzymes after administration into the body, whilst remaining chemically stable for a significantly longer period under validated laboratory storage conditions. On the other hand, a peptide may undergo chemical degradation in solution even in the absence of biological enzymes.
Potential degradation mechanisms under laboratory conditions may include hydrolysis of peptide bonds, oxidation of susceptible residues, terminal group modifications, aggregation, surface adsorption, and pH- and formulation-related changes.
The Epitalon sequence contains glutamic acid and aspartic acid, which have side chains containing carboxyl groups. Its physicochemical properties may therefore depend on the degree of ionisation and the pH of the environment.
Research summarised in a 2025 review also shows that interactions between Epitalon and modelled carrier systems can vary depending on pH due to electrostatic interactions involving negatively charged carboxyl groups. [1]
This does not constitute a recommendation regarding storage pH. It merely shows that the physicochemical properties of Epitalon depend on the environment.
How Temperature, Light and Multiple Manipulations Can Affect Peptides?
Temperature, light exposure, repeated handling of the preparation and freeze-thaw cycles can affect peptide formulations through chemical degradation, aggregation, adsorption, contamination or changes in concentration. However, there is no peer-reviewed Epitalon study establishing exact temperature limits, light tolerance or a validated number of freeze-thaw cycles for Epitalon solutions.
Temperature is one of the most important parameters in pharmaceutical stability testing, as the rate of chemical reactions changes with temperature.
However, this general rule does not justify determining a specific storage time for Epitalon in the fridge without adequate data.
Claims such as:
„Epitalon remains stable for 30 days after reconstitution.,
„Epitalon keeps for six months in the fridge,
or
„lyophilised Epitalon remains stable for two years at a specified temperature”
they require stability data for the specific Epitalon formulation.
The peer-reviewed studies analysed for this article do not establish such universal periods.
FDA guidelines for lyophilised pharmaceutical products show how stability should be established: studies should include the aged lyophilised product and an evaluation of the reconstituted preparation for the maximum period stated on the label, including testing at appropriate concentrations.
This means that the shelf life should be based on data rather than established practice.
Temperature
Higher temperatures can accelerate many degradation reactions, whereas freezing can cause other types of stress related to ice formation, local increases in substance concentration, pH changes or aggregation.
It was not sufficiently specified whether and to what extent these processes affect AEDG at specific temperatures in Epitalon-specific stability studies.
Light
Some peptides and formulation ingredients may undergo photochemical degradation.
However, the reviewed literature does not contain a controlled photostability study of Epitalon that would determine the level of light exposure causing measurable degradation.
Therefore, one should not create a precise exposure limit for light specific to Epitalon without appropriate data.
Multiple manipulation
Repeated opening or use of the vial can introduce several variables: temperature fluctuation cycles, risk of contamination, evaporation, surface interactions, oxidation, and the effects of repeated freezing and thawing.
Also in this case, there is no peer-reviewed Epitalon dataset confirming that the preparation remains unchanged after a specified number of such cycles.
In laboratory quality control, these parameters should derive from validated test procedures or the stability documentation of the specific product.
What Storage Information Should the Supplier Provide?
A scientifically useful Epitalon specification should define material identity, the chemical form of the peptide, stated content or purity, batch number, storage conditions, the basis for the expiry or re-test date, storage conditions for the solution after reconstitution if validated, and the analytical methods confirming this information. Statements regarding storage without stability data should be treated as manufacturer specifications rather than independently verified facts concerning Epitalon.
In the case of a research peptide, the documentation should ideally distinguish between the unopened dry material and the prepared solution.
| Information | Why it matters |
|---|---|
| Peptide identity | Confirms that the material contains AEDG and not another sequence |
| Batch or lot number | It combines documentation with specific material |
| Tagged content/purity | Indicates the amount of characterised target peptide |
| Analytical method | It shows how identity and purity were assessed |
| Chemical form/salt form | It may affect mass calculations and physicochemical properties |
| Storage conditions for the dry product | They determine the validated procedure prior to preparation |
| Expiry or re-examination date | It indicates a period supported by supplier data |
| Stability after reconstitution | It shows whether the stability of the solution has actually been investigated |
| Temperature deviations | They make it possible to evaluate whether going out of range invalidates the specification |
| Light sensitivity | It only has meaning when it is confirmed or specified |
| Sterility/endotoxin specification | Crucial when the experiment requires sterile material |
| Transport conditions | They help to determine whether the material has remained compliant with the specification |
Analytical confirmation of identity is of particular importance in the case of Epitalon.
Vanhee et al. developed an LC-MS/MS method enabling the identification of Epitalon in unauthorised pharmaceutical preparations and distinguishing it from a closely related sequence. [4] A 2025 review of Epitalon cites this study as evidence that mass spectrometry analysis can confirm the identity of Epitalon rather than relying solely on product labelling.
Merely stating the storage temperature therefore does not constitute sufficient quality documentation.
The scientifically significant question is:
What experimental stability data supports this storage temperature and time for this specific formulation and batch type?
Why Reconstruction Instructions Must Match the Product Specification
Reconstitution instructions must correspond to the specific Epitalon product, as the peptide form, purity, excipients, target concentration, packaging system, sterility requirements and validated stability may vary. Copying the solvent volume or preparation procedure from another study or product may lead to a different concentration and a stability assumption that is not supported by data.
Published research on Epitalon clearly shows why methods should not be generalised.
In the 2025 ARPE-19 study, Epitalon was prepared in water and then diluted in culture medium. [2]
In a 2025 telomere study, the experimental solution was prepared using bacteriostatic water. [3]
Both methods provided solutions suitable for specific experiments.
None of them constitutes a universal procedure for every Epitalon vial.
Product specifications may vary in a way that affects preparation. One material may be supplied as a free peptide and another as a salt. One may contain excipients added during lyophilisation. Another may be intended solely for chemical analysis and not for sterile cell culture.
Reconstitution can also affect concentration accuracy. If researchers assume that each vial contains exactly the nominal mass of peptide without checking the stated content and formulation details, the final experimental concentrations may be incorrect.
Stability declarations must also correspond to the specific product. General FDA guidelines on lyophilised products emphasise that stability assessment should cover the reconstituted material and concentrations appropriate for the stated shelf life.
Validated conditions for one product cannot therefore be automatically transferred to another simply because both are labelled as „Epitalon”.
Is There a Published Shelf Life of Epitalon After Reconstitution?
In the analysed evidence, no single, universally peer-reviewed shelf-life for reconstituted Epitalon was identified. Published studies show that researchers have successfully prepared aqueous solutions of Epitalon for specific experiments, but have not established standardised seven-day, thirty-day or other periods through formal studies of activity, degradation, sterility and biological activity. [1–3]
This is one of the most important conclusions on this topic.
The fact that the prepared Epitalon solution was used for several experimental days in the study does not mean that it was a formal stability study.
For example, in the 2025 telomere study, cancer cells were exposed daily for four days, and normal cells daily for three weeks. [3]
This information describes the experimental setup.
However, this does not automatically indicate how the stock solution was stored during this period, whether fresh batches were prepared, how the integrity of the peptide was monitored, or whether HPLC or LC-MS confirmed that the concentration remained unchanged after storage.
Therefore, the three-week experiment should not be cited as proof that reconstituted Epitalon is stable for three weeks.
Similarly, in a 2025 study of retinal cells, Epitalon was used for 24–72 hours, but this does not establish a universal 72-hour storage specification. [2]
Treatment duration and shelf-life of the solution are two distinct scientific questions.
Is lyophilised Epitalon more stable than reconstituted Epitalon?
Freeze-drying is generally used to improve the storage properties of molecules that may be less stable in aqueous solution. However, there is no peer-reviewed comparison specific to Epitalon that would determine the exact stability advantage, shelf-life or degradation rate of freeze-dried and reconstituted AEDG under specific storage conditions.
Freeze-drying reduces the amount of free water available for many degradative processes and is widely used for pharmaceutical peptide and protein products.
This general rule explains why peptides are often supplied in the form of a lyophilised powder.
However, the statement „lyophilised peptides are more stable” does not say:
how long does Epitalon remain within specification,
What is the optimum temperature?,
What is the permissible residual moisture content?,
is light protection necessary,
nor how quickly degradation proceeds after reconstitution.
Real stability studies are required to answer these questions.
FDA guidance on lyophilised parenteral products specifically indicates that stability evaluation should take into account residual moisture and testing of the aged product after reconstitution, rather than assuming that lyophilisation alone guarantees stability.
This is of particular significance for Epitalon, as the current peer-reviewed literature contains extensive biological research, but relatively limited formulation and stability characterisation. [1]
Does Epitalon require storage in the fridge?
The analysed peer-reviewed literature concerning Epitalon does not establish a universal requirement for refrigeration or a validated refrigerated storage time for all Epitalon preparations. Instructions regarding refrigeration should therefore derive from stability data for the specific formulation, rather than from general assumptions concerning peptides or commercial practices.
Such an answer may be less convenient than giving a specific temperature, but it is scientifically more justified.
Temperature requirements may depend on whether the peptide is:
dry or dissolved,
free peptide or salt,
formulated with excipients,
sterile or non-sterile,
intended for chemical analysis or cell culture,
and packed under conditions validated by the manufacturer.
The supplier may specify storage in a refrigerator or freezer based on their own stability studies. If such data are available, the specification for the specific material may be used.
However, such a specification should be described as product-specific rather than as a universal fact resulting from the published pharmacology of Epitalon.
The same principle applies after reconstitution.
Without a validated Epitalon solution stability study, the literature does not justify specifying one exact storage period in the fridge.
Can Epitalon be frozen after reconstitution?
No universal, evidence-based freezing and thawing protocol for reconstituted Epitalon has been established. Freezing may, under certain conditions, help preserve peptide solutions, but it can also cause concentration changes, pH shifts, aggregation, surface interactions, or other types of stress. Therefore, handling procedures related to freezing and thawing should be based on validated laboratory data for the specific product.
A common laboratory practice with unstable solutions is to divide them into portions and limit the number of freeze-thaw cycles.
This is a general laboratory principle, not a specifically validated rule for Epitalon.
No study in the analysed material specifies:
optimum freezing temperature,
validated freeze-thaw cycles,
maximum storage time in the frozen state,
nor the percentage content of unchanged AEDG after repeated freezing.
Without such measurements, claims such as „Epitalon withstands X freeze-thaw cycles” would be speculative.
An ideal stability study of Epitalon should evaluate the identity and concentration of the peptide using validated analytical methods before and after controlled temperature cycling regimes.
HPLC and LC-MS would be particularly relevant, as it has already been demonstrated that Epitalon can be identified using LC-MS/MS. [4]
Reconstitution and Stability of Epitalon — Summary of Evidence
| Question | An evidence-based response |
|---|---|
| Can Epitalon be dissolved in water? | Yes; it was used in a 2025 cell study. [2] |
| Has bacteriostatic water been used experimentally? | Yes; in a 2025 study on human cells. [3] |
| Does this prove that bacteriostatic water is always required? | Not |
| Does the 10 mg vial indicate the dose or the concentration? | Not |
| Is there a peer-reviewed universal reconstitution ratio? | Not |
| Is there a validated universal shelf life after reconstitution? | Not |
| Is there a validated universal refrigerator storage time? | Not |
| Has a specific freeze-thaw cycle limit for Epitalon been established? | Not set |
| Is the exact exposure limit to light known? | Not set |
| Does freeze-drying matter for stability? | Generally yes, but the exact advantage for Epitalon has not been quantified |
| Are the supplier's storage declarations universal scientific facts? | No; they are product-specific unless they have been independently validated |
| Can LC-MS help confirm the identity of Epitalon? | Yes. [4] |
The main gap in the evidence does not concern whether Epitalon can be dissolved. It concerns the lack of a robust, Epitalon-specific set of pharmaceutical data determining the stability, storage and reconstitution of various formulations.
Frequently Asked Questions about Epitalon Reconstitution and Storage
What does Epitalon reconstitution mean?
Reconstitution of Epitalon refers to the preparation of dry or lyophilised AEDG material as a solution using a solvent suitable for the specific laboratory product and experiment. Published studies have used aqueous solutions, but reconstitution alone does not determine how long the solution remains chemically stable, sterile or biologically active.
Is bacteriostatic water required for Epitalon?
No such universal requirement has been established. In a 2025 study of telomeres in human cells, bacteriostatic water was used to prepare the Epitalon stock solution, whilst in a separate 2025 study on human retinal cells, Epitalon was dissolved in water. [2,3] The appropriate solvent therefore depends on the specifics of the experiment, rather than on a single universal rule for Epitalon.
How much bacteriostatic water should be added to 10 mg of Epitalon?
Published literature does not specify a single universal evidence-based quantity. The chosen volume determines the final concentration and must correspond to a specific laboratory protocol and product specification. The proportion used in one cell culture experiment should not be converted into general instructions for self-administration.
How long does Epitalon remain stable after reconstitution?
No universal shelf life following reconstitution has been established in peer-reviewed stability studies of Epitalon. Experimental publications describe the preparation of Epitalon solutions, but generally do not present formal HPLC/LC-MS degradation curves, sterility tests, activity measurements or validated expiry dates for these solutions.
Does Epitalon need to be stored in the fridge after reconstitution?
The analysed peer-reviewed evidence does not establish a single refrigerated storage period specific to Epitalon. Temperature requirements should therefore derive from validated stability data for the specific formulation, rather than an assumed number of days based on general peptide practices.
How long does lyophilised Epitalon remain stable?
No single, universally accepted, peer-reviewed shelf life has been established for freeze-dried Epitalon. Freeze-drying is generally used to improve storage properties, but actual stability depends on the formulation, residual moisture content, packaging, temperature and other parameters requiring product-specific testing.
Can reconstituted Epitalon be frozen?
The literature does not establish a validated freezing and thawing protocol for Epitalon. Freezing may affect the properties of the solution, and none of the reviewed peer-reviewed studies specify the optimal freezing temperature, storage time, or acceptable number of freeze-thaw cycles for reconstituted AEDG.
Does a 10 mg vial mean that the solution has a concentration of 10 mg/mL?
No. Ten milligrams means the nominal total mass of material in the vial, whereas mg/mL is a unit of concentration and requires knowledge of the final volume of the solution. A vial labelled as 10 mg therefore does not have a defined concentration in mg/mL until a validated preparation volume is defined.
Does bacteriostatic water keep Epitalon stable for a specified number of days?
This has not been established. A bacteriostatic agent is intended to limit the growth of microorganisms, but it does not automatically prevent chemical degradation of the peptide, aggregation, adsorption, oxidation, or other physicochemical changes. Microbiological protection and chemical stability are distinct properties.
Limitations of Epitalon Stability Evidence
The greatest limitation is the attempt to use biological assays to answer questions concerning pharmaceutical stability for which they were not designed.
A study in which cells were exposed to the peptide for three weeks is not automatically a three-week stability study.
The study in which Epitalon was dissolved in water does not prove that every formulation should be prepared in water.
A publication using bacteriostatic water does not prove that it is always a better solvent.
And the provision by the supplier of a specified shelf-life does not turn this declaration into independent, peer-reviewed scientific evidence.
The 2025 Epitalon review itself highlights significant gaps in the physicochemical and pharmaceutical characterisation of the peptide and notes that chemical modifications to increase stability have not been adequately studied for Epitalon. [1]
Future formulation research should ideally include:
chemical purity over time,
concentration of unchanged AEDG,
main degradation products,
pH dependence,
temperature dependence,
photostability,
residual moisture of lyophilised formulations,
effect of freezing and thawing,
adsorption onto the packaging material,
aggregation,
sterility,
endotoxins where it matters,
and biological activity after storage.
Such data could serve as a basis for determining reliable storage temperatures and shelf lives.
Until such evidence is obtained, precise claims such as „reconstituted Epitalon is stable for X days” should be attributed to the specific manufacturer or specific formulation that generated the relevant data, rather than presented as a universal scientific fact.
Disclaimer
This article is for educational and scientific-informational purposes only, intended for a laboratory context. It does not constitute medical advice, dosage recommendations, injection instructions, reconstitution instructions for self-administration, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and published research does not define a standardised, FDA- or EMA-approved method of reconstitution, storage period, method of preparation for human use, or post-reconstitution shelf-life for the discussed applications. Much of the available information comes from laboratory or preclinical experiments rather than validated pharmaceutical stability studies. Any laboratory preparation should be carried out in accordance with exact product specifications, institutional procedures, validated analytical methods, and relevant safety requirements.
References
[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
[2] Gatta, M., Dovizio, M., Milillo, C., Ruggieri, A. G., Sallese, M., Antonucci, I., Trofimov, A., Khavinson, V., Trofimova, S., Bruno, A., & Ballerini, P. (2025). The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Reviews and Reports, 21(6), 1822–1834. https://doi.org/10.1007/s12015-025-10911-x
[3] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x
[4] Vanhee, C., Moens, G., Van Hoeck, E., Deconinck, E., & De Beer, J. O. (2015). Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis, 7(3), 259–264. https://doi.org/10.1002/dta.1771